在吸烟严重精神疾病的人群中,将瓦雷尼克林预加载与接受和承诺治疗 (ACT) 结合起来:随机 ACTSLow 试点可行性试验
Robert M Anthenelli1, Benjamin S McKenna2, Jillian Giannini1
1Pacific Treatment and Research Center, Department of Psychiatry, University of California, San Diego, 3252 Holiday Court, Suite 200, La Jolla, CA 92037, United States.
Drug and alcohol dependence
|November 6, 2023
概括
这项试点研究发现,将瓦雷尼克林与接受和承诺疗法 (ACT) 结合起来,可以在严重精神疾病 (SMI) 患者中戒烟. 观察到高满意度和坚持,支持进一步的试验.
科学领域:
- 精神病学是一个精神病学.
- 成 药物 药物 药物 药物
- 行为治疗是一种行为疗法.
背景情况:
- 患有严重精神疾病 (SMI) 的个人,包括双相情感障碍 (BD) 和精神分裂症谱系障碍 (SSD),在戒烟方面面临重大挑战.
- 与普通人群相比,患有SMI的吸烟者在试图戒烟时,戒烟率较低,神经精神疾病不良事件 (NPSAE) 的风险更高.
研究的目的:
- 试点测试将瓦雷尼克林预加载与接受和承诺治疗 (ACT) 结合在SMI患者中戒烟的可行性.
- 评估两种不同的瓦雷尼克林剂量策略与ACT结合,以提高戒烟率而不会增加NPSAE.
主要方法:
- 一个为期12周的随机,双盲试点可行性试验,涉及患有BD或SSD的参与者.
- 低剂量 (0.5mg两次一天) 与标准剂量 (1.0mg两次一天) 瓦伦尼克林的比较,所有参与者都接受了ACT会议.
- 灵活的目标戒烟日 (TQD) 到35日,在戒烟之前使用瓦伦尼克林.
主要成果:
- 由于COVID-19和瓦雷尼克林召回,招聘面临挑战,但保留目标得到了满足.
- 在各组中报告了高治疗满意度和对预加载和灵活的TQD的坚持 (92.9%).
- 12周的7天流行点禁欲率在BD参与者中为37.5%,在SSD参与者中为16.7%,在标准瓦伦尼克林剂量下;药物耐受性良好.
结论:
- 尽管招募障碍,但瓦雷尼克林和ACT的结合方法证明了在SMI患者中戒烟的可行性.
- 参与者的高度坚持和满意度表明这种联合治疗是一种有前途的策略.
- 研究结果支持进行全力以赴的试验,以测试这种干预措施,特别是在吸烟的双相情感障碍患者中.
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252
COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Treatment Strategies for Psychological Disorders
143
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
143
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K


